Nkarta (NKTX) Gets a Buy from Leerink Partners
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.
Leerink Partners Remains a Buy on Century Therapeutics (IPSC)
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...
The Star5d
Indochina Bank launches the newest product ‘Daina Pay’ to support our customer in times of need
VIENTIANE: The Indochina Bank has officially launched its latest product, the ‘Daina Pay’, to facilitate transactions including the payment of urgent bills. The bank’s managing director ...
Beyond The Numbers: 13 Analysts Discuss Merck & Co Stock
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $112.46, a high ...
Tribute5d
Daina Leitold Biography & Movies
Academy Award-nominated actor John Lithgow is reportedly closing in on a deal to play Headmaster Albus Dumbledore in the upcoming HBO Harry Potter series. Celebrity AI video protests Kanye West ...
ETF Daily News3d
Leerink Partnrs Comments on Nkarta FY2029 Earnings
Leerink Partnrs analyst D. Graybosch anticipates that the company will post earnings per share of ($1.74) for the year. The consensus estimate for Nkarta’s current full-year earnings is ($1.68 ...
ETF Daily News4d
What is Leerink Partnrs’ Forecast for FATE Q1 Earnings?
Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings per share of ($0.46) for the quarter. The consensus estimate for Fate Therapeutics’ current ...